Norges Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Norges Bank’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,531,080	Closed	-$448M	–	200
2025 Q4	$448M	Buy	+7,531,080	New	+$410M	0.05%	335
2025 Q3	–	Sell	-2,043,879	Closed	-$112M	–	226
2025 Q2	$112M	Sell	2,043,879 -1,264,506	-38%	-$74.5M	0.01%	660
2025 Q1	$234M	Sell	3,308,385 -261,446	-7%	-$17.6M	0.03%	418
2024 Q4	$235M	Buy	3,569,831 +36,288	+1%	+$2.43M	0.03%	428
2024 Q3	$248M	Sell	3,533,543 -85,960	-2%	-$7.19M	0.03%	415
2024 Q2	$298M	Buy	3,619,503 +140,991	+4%	+$11.7M	0.04%	349
2024 Q1	$304M	Buy	3,478,512 +117,202	+3%	+$10.5M	0.05%	336
2023 Q4	$324M	Buy	3,361,310 +318,010	+10%	+$28.1M	0.06%	299
2023 Q3	$269M	Buy	3,043,300 +6,801	+0.2%	+$605K	0.05%	311
2023 Q2	$263M	Buy	3,036,499 +152,016	+5%	+$14.3M	0.05%	324
2023 Q1	$280M	Buy	2,884,483 +130,466	+5%	+$13.5M	0.06%	292
2022 Q4	$285M	Buy	2,754,017 +157,654	+6%	+$14.8M	0.07%	275
2022 Q3	$220M	Buy	2,596,363 +32,727	+1%	+$2.91M	0.06%	309
2022 Q2	$212M	Buy	2,563,636 +5,338	+0.2%	+$425K	0.05%	316
2022 Q1	$197M	Buy	2,558,298 +208,758	+9%	+$17.5M	0.04%	388
2021 Q4	$208M	Buy	2,349,540 +223,693	+11%	+$18.5M	0.04%	396
2021 Q3	$164M	Sell	2,125,847 -42,198	-2%	-$3.33M	0.04%	460
2021 Q2	$181M	Sell	2,168,045 -26,274	-1%	-$2.08M	0.04%	443
2021 Q1	$166M	Buy	2,194,319 +744,823	+51%	+$60.8M	0.04%	446
2020 Q4	$127M	Buy	1,449,496 +32,054	+2%	+$2.54M	0.03%	513
2020 Q3	$108M	Sell	1,417,442 -60,415	-4%	-$6.11M	0.03%	512
2020 Q2	$182M	Sell	1,477,857 -75,441	-5%	-$7.5M	0.05%	322
2020 Q1	$131M	Sell	1,553,298 -199,543	-11%	-$17.2M	0.05%	352
2019 Q4	$148M	Buy	1,752,841 +245,138	+16%	+$18.5M	0.04%	402
2019 Q3	$102M	Sell	1,507,703 -229,622	-13%	-$17.7M	0.03%	505
2019 Q2	$149M	Buy	1,737,325 +256,507	+17%	+$21.9M	0.05%	377
2019 Q1	$132M	Buy	1,480,818 +293,094	+25%	+$27.2M	0.04%	401
2018 Q4	$101M	Buy	1,187,724 +117,982	+11%	+$11.2M	0.04%	437
2018 Q3	$104M	Buy	1,069,742 +109,408	+11%	+$10.9M	0.03%	485
2018 Q2	$90.5M	Buy	960,334 +44,480	+5%	+$3.9M	0.03%	523
2018 Q1	$74.2M	Buy	915,854 +37,798	+4%	+$3.24M	0.03%	594
2017 Q4	$78.3M	Buy	878,056 +136,767	+18%	+$11.9M	0.03%	570
2017 Q3	$69M	Hold	741,289	–	–	0.03%	606
2017 Q2	$67.3M	Sell	741,289 -195,124	-21%	-$17.8M	0.03%	596
2017 Q1	$82.2M	Sell	936,413 -77,013	-8%	-$6.85M	0.03%	489
2016 Q4	$84M	Buy	1,013,426 +26,046	+3%	+$2.24M	0.04%	476
2016 Q3	$87.3M	Buy	987,380 +36,542	+4%	+$3.44M	0.04%	438
2016 Q2	$74M	Sell	950,838 -159,423	-14%	-$13.6M	0.04%	486
2016 Q1	$91.6M	Sell	1,110,261 -57,295	-5%	-$4.66M	0.05%	389
2015 Q4	$122M	Sell	1,167,556 -9,470	-0.8%	-$989K	0.06%	291
2015 Q3	$124M	Buy	1,177,026 +174,011	+17%	+$23.2M	0.07%	297
2015 Q2	$137M	Buy	1,003,015 +40,944	+4%	+$5.07M	0.07%	281
2015 Q1	$120M	Sell	962,071 -82,532	-8%	-$8.74M	0.06%	320
2014 Q4	$94.4M	Sell	1,044,603 -72,230	-6%	-$6.01M	0.05%	366
2014 Q3	$80.6M	Sell	1,116,833 -1,116,833	-50%	-$73.4M	0.04%	409
2014 Q2	$139M	Buy	2,233,666 +1,116,833	+100%	+$67.5M	0.04%	468
2014 Q1	$76.2M	Sell	1,116,833 -62,275	-5%	-$4.59M	0.04%	403
2013 Q4	$82.9M	Sell	1,179,108 -367,869	-24%	-$25M	0.05%	362
2013 Q3	$112M	Buy	1,546,977 +949,969	+159%	+$63.1M	0.07%	296
2013 Q2	$33.3M	Buy	+597,008	New	+$37.2M	0.02%	722

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank's BMRN Position: Q1 2026 in Review

Norges Bank sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 7,531,080 shares — an estimated $448M sold.

Norges Bank first reported a position in BMRN in Q2 2013 and held it in 50 quarters. The position peaked at $448M in Q4 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Norges Bank reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Norges Bank sold 7,531,080 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $448M.
Norges Bank first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 50 quarters.
Norges Bank's BioMarin Pharmaceuticals position peaked at $448M in Q4 2025.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Norges Bank's 13F filing for Q1 2026.